Evidence map›Paper›PMID 37205710›Full record

ArticlePLoS biology2023

Systems biology elucidates the distinctive metabolic niche filled by the human gut microbe Eggerthella lenta.

Cecilia Noecker, Juan Sanchez, Jordan E Bisanz, Veronica Escalante, Margaret Alexander, Kai Trepka, Almut Heinken, Yuanyuan Liu, Dylan Dodd, Ines Thiele and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Anaerobic riboflavin degradation by human gutJournal of bacteriology · 2026
    Article
  5. Article
  6. Research square · 2026
    Article
  7. bioRxiv : the preprint server for biology · 2026
    Article
  8. Review
  9. Article
  10. Female-enrichedbioRxiv : the preprint server for biology · 2026
    Article
  11. Review
  12. Anaerobic riboflavin degradation by human gutbioRxiv : the preprint server for biology · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Cecilia NoeckerDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, California, United States of America.
Juan SanchezChan Zuckerberg Biohub-San Francisco, San Francisco, California, United States of America.
Jordan E BisanzDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, California, United States of America.
Veronica EscalanteDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, California, United States of America.
Margaret AlexanderDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, California, United States of America.
Kai TrepkaDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, California, United States of America.
Almut HeinkenSchool of Medicine, National University of Ireland, Galway, Ireland.
Yuanyuan LiuDepartment of Pathology, Stanford University, Stanford, California, United States of America.
Dylan DoddDepartment of Pathology, Stanford University, Stanford, California, United States of America.
Ines ThieleSchool of Medicine, National University of Ireland, Galway, Ireland.
Brian C DeFeliceChan Zuckerberg Biohub-San Francisco, San Francisco, California, United States of America.
Peter J TurnbaughDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, California, United States of America.ORCID 0000-0002-0888-2875
University of California, San Francisco · USChan Zuckerberg Initiative (United States) · USOllscoil na Gaillimhe – University of Galway · IEStanford University · US

Funding

Project 4 - Mechanistic studies on the role of the gut microbiome in models for Alzheimer's diseaseU19AG063744 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ROB KNIGHT, Rima F Kaddurah-Daouk · 2019 to 2026
$54.1M
Maximizing Opportunities for Research Excellence - Evaluation Training SupplementR25GM056847 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DUNCAN, D'ANNE S., SELLO, JASON K · 1998 to 2023
$14.1M
Medical Scientist Training Program (T32 NRSA Training Grant)T32GM141323 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Aimee Kao · 2021 to 2026
$10.5M
Microbial Pathogenesis and Host DefenseT32AI060537 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanne N. Engel · 2004 to 2026
$6.5M
Predicting and preventing drug metabolism by the human gut microbiomeR01HL122593 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Peter James Turnbaugh · 2016 to 2026
$5.7M
Gut Liver Brain Biochemical Axis in Alzheimer's DiseaseRF1AG058942 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, VAN DUIJN, CORNELIA MARJA · 2018 to 2018
$3.4M
Microbiota-based probiotics to treat inborn errors in metabolismR01AT011396 · NCCIH · STANFORD UNIVERSITY · PI Dylan Dodd · 2022 to 2026
$2.9M
Host-microbiome interactions shape the metabolic effects of ketogenic dietsR01DK114034 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TURNBAUGH, PETER JAMES · 2020 to 2024
$2.5M
Physiology of bacterial metabolism in the human gut microbiomeR35GM142873 · NIGMS · STANFORD UNIVERSITY · PI DODD, DYLAN · 2021 to 2025
$2.0M
Establishing the feasibility of editing the human gut microbiomeR01AT011117 · NCCIH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TURNBAUGH, PETER JAMES · 2020 to 2023
$1.6M
Modulation of gut bacteria-derived host metabolitesK08DK110335 · NIDDK · STANFORD UNIVERSITY · PI DODD, DYLAN · 2018 to 2021
$573k
Systems-level analysis of the metabolism and ecology of genetically intractable gut bacteriaF32GM140808 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NOECKER, CECILIA · 2021 to 2022
$134k
NCCIH NIH HHS R01 AT011117NCCIH NIH HHS R01 AT011396NHLBI NIH HHS R01 HL122593NIAID NIH HHS T32 AI060537NIA NIH HHS RF1 AG058942NIA NIH HHS U19 AG063744NIDDK NIH HHS K08 DK110335NIDDK NIH HHS R01 DK114034NIGMS NIH HHS F32 GM140808NIGMS NIH HHS R25 GM056847NIGMS NIH HHS R35 GM142873NIGMS NIH HHS T32 GM141323
6 · The paper itself

Abstract

Human gut bacteria perform diverse metabolic functions with consequences for host health. The prevalent and disease-linked Actinobacterium Eggerthella lenta performs several unusual chemical transformations, but it does not metabolize sugars and its core growth strategy remains unclear. To obtain a comprehensive view of the metabolic network of E. lenta, we generated several complementary resources: defined culture media, metabolomics profiles of strain isolates, and a curated genome-scale metabolic reconstruction. Stable isotope-resolved metabolomics revealed that E. lenta uses acetate as a key carbon source while catabolizing arginine to generate ATP, traits which could be recapitulated in silico by our updated metabolic model. We compared these in vitro findings with metabolite shifts observed in E. lenta-colonized gnotobiotic mice, identifying shared signatures across environments and highlighting catabolism of the host signaling metabolite agmatine as an alternative energy pathway. Together, our results elucidate a distinctive metabolic niche filled by E. lenta in the gut ecosystem. Our culture media formulations, atlas of metabolomics data, and genome-scale metabolic reconstructions form a freely available collection of resources to support further study of the biology of this prevalent gut bacterium.

Indexed as

ActinobacteriaGastrointestinal MicrobiomeAnimalsEcosystemHumansMiceSystems Biology

Identifiers

PMID37205710
PMCPMC10234575
OpenAlexW4377116085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.